The Chemical Entities of Biological Interest (ChEBI) ontology is downloaded weekly from EMBL-EBI at http://www.ebi.ac.uk/chebi/. The data is made available under the Creative Commons License (CC BY 3.0, http://creativecommons.org/licenses/by/3.0/). For more information see: Degtyarenko et al. (2008) ChEBI: a database and ontology for chemical entities of biological interest. Nucleic Acids Res. 36, D344–D350.
The 6-O-methyl ether of erythromycin A, clarithromycin is a macrolide antibiotic used in the treatment of respiratory-tract, skin and soft-tissue infections. It is also used to eradicate Helicobacter pylori in the treatment of peptic ulcer disease. It prevents bacteria from growing by interfering with their protein synthesis.
Clarithromycin inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid] Clarithromycin results in decreased activity of ABCB11 protein
Clarithromycin results in decreased activity of CYP3A4 protein Clarithromycin results in decreased expression of CYP3A4 mRNA [Ofloxacin co-treated with Clarithromycin] inhibits the reaction [CYP3A4 protein results in increased metabolism of Theophylline]; Clarithromycin inhibits the reaction [CYP3A4 protein results in increased hydroxylation of Testosterone]; Clarithromycin inhibits the reaction [CYP3A4 protein results in increased metabolism of Disopyramide]
[IFNG protein co-treated with IL1A protein co-treated with TNF protein co-treated with lipopolysaccharide, Escherichia coli O111 B4] results in increased susceptibility to Clarithromycin
[IFNG protein co-treated with IL1A protein co-treated with TNF protein co-treated with lipopolysaccharide, Escherichia coli O111 B4] results in increased susceptibility to Clarithromycin; [IL6 protein co-treated with IL1A protein co-treated with TNF protein co-treated with lipopolysaccharide, Escherichia coli O111 B4] results in increased susceptibility to Clarithromycin
[IL6 protein co-treated with IL1A protein co-treated with TNF protein co-treated with lipopolysaccharide, Escherichia coli O111 B4] results in increased susceptibility to Clarithromycin Clarithromycin results in decreased expression of IL6 mRNA
[KCNE2 protein mutant form binds to KCNH2 protein] which results in increased susceptibility to Clarithromycin Clarithromycin results in decreased activity of KCNH2 protein
[IFNG protein co-treated with IL1A protein co-treated with TNF protein co-treated with lipopolysaccharide, Escherichia coli O111 B4] results in increased susceptibility to Clarithromycin; [IL6 protein co-treated with IL1A protein co-treated with TNF protein co-treated with lipopolysaccharide, Escherichia coli O111 B4] results in increased susceptibility to Clarithromycin Clarithromycin results in decreased expression of TNF mRNA